- 126 Downloads
Aciclovir (acyclovir) is a nucleoside analogue with antiviral activity in vitro against the herpes simplex viruses (HSV), varicella zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV) and human herpesvirus 6 (HHV-6).
Topical, oral or intravenous aciclovir is well established in the treatment of ophthalmic, mucocutaneous and other HSV infections, with intravenous aciclovir the accepted treatment of choice in herpes simplex encephalitis. The efficacy of aciclovir is increased with early (preferably during the prodromal period) initiation of treatment but, despite significant clinical benefit, viral latency is not eradicated, and pretreatment frequencies of recurrence usually continue after episodic acute treatment is completed. Intravenous administration has also shown benefit in the treatment of severe complications of HSV infection in pregnancy, and neonatal HSV infections. Recurrence of HSV has been completely prevented or significantly reduced during suppressive therapy with oral aciclovir in immunocompetent patients.
Use of oral aciclovir is effective but controversial in the treatment of otherwise healthy individuals with varicella (chickenpox), and in some countries it has been recommended for use only in cases which may be potentially severe. The development of rash and pain associated with herpes zoster (shingles) is attenuated with oral or intravenous aciclovir therapy, ocular involvement is prevented, and post-herpetic neuralgia appears to be decreased. Similarly, in a few patients with zoster ophthalmicus, oral aciclovir has reduced the frequency and severity of long term ocular complications and post-herpetic neuralgia, and herpes zoster oticus is improved with intravenous aciclovir.
Oral aciclovir has prevented recurrence of HSV genital or orofacial infections during suppressive therapy in > 70% of immunocompetent patients in most clinical trials. Suppression of latent HSV, VZV and CMV infections has been achieved in many immunocompromised patients receiving the oral or intravenous formulations. Aciclovir also appears to offer partial protection from invasive CMV disease in CMV-seropositive bone marrow transplant recipients.
The few comparative trials published have shown aciclovir to be at least as effective as other investigated antivirals in the treatment of HSV infections in immunocompetent patients, and more effective than inosine pranobex in the prophylaxis of genital herpes. Similarly, in isolated clinical trials, oral aciclovir appears as effective as topical idoxuridine and oral brivudine in some parameters in immunocompetent patients with VZV infections, and the intravenous formulation appears at least as effective as oral brivudine and intravenous vidarabine in treating these infections in immunocompromised patients. Investigations of a regimen of aciclovir plus zidovudine in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) suggest some advantage for the combination over zidovudine monotherapy in reducing the incidence of opportunistic infections and mortality. However, patient numbers were limited and these preliminary results require substantiation.
Aciclovir is well tolerated. Mild gastrointestinal effects may occur with the oral formulation in a few patients, and acute reversible renal failure and neurotoxicity has been associated with high peak plasma aciclovir concentrations, usually in patients receiving intravenous administration.
Thus, aciclovir in intravenous, oral and to a lesser extent topical formulations retains its secure position as an effective agent in the therapy and prophylaxis of HSV and VZV infections in immunocompetent and immunocompromised patients, with no clear advantages shown for newer agents over aciclovir in limited comparisons. The role of aciclovir in the prevention of CMV infections in immunocompromised patients is also generally accepted, but its use in diseases caused by other herpes viruses such as EBV and HHV-6 has not been supported in clinical investigations to date. Nonetheless, there appears to be potential for further growth in the role of aciclovir if combination regimens become more accepted in the treatment of viral infections, and if its efficacy in reducing opportunistic infections and associated mortality in patients with AIDS or ARC is confirmed.
Aciclovir (acyclovir) selectively inhibits DNA replication of herpes viruses, with low host cell toxicity. The antiviral is preferentially activated in infected cells; initial phosphorylation occurs via viral thymidine kinase, and aciclovir triphosphate (the active derivative obtained from the monophosphate via host cell enzymes) inhibits viral DNA polymerase more readily than the cellular enzyme, thus preventing viral replication. Although Epstein-Barr virus (EBV) appears to have only minimal thymidine kinase activity, EBV DNA polymerase is very susceptible to inhibition by aciclovir triphosphate. Since cytomegalovirus (CMV) does not code for thymidine kinase, and CMV DNA polymerase is poorly inhibited by aciclovir triphosphate formed by cellular enzymes, CMV is less susceptible to aciclovir than are herpes simplex virus (HSV), varicella zoster virus (VZV) and EBV.
In descending order of susceptibility, the viruses against which aciclovir exhibits in vitro antiviral activity are HSV-1 and 2, VZV, EBV, human herpesvirus 6 (HHV-6) and CMV. The in vitro activity of aciclovir was generally similar to or greater than that of most other antiviral agents tested against HSV and VZV; ganciclovir, idoxuridine and vidarabine are more potent than aciclovir against CMV; ganciclovir and foscarnet appear to be more potent against HHV-6; and aciclovir appears to have greater activity than penciclovir against EBV. Combination of aciclovir with various antiviral compounds has resulted in synergistic or additive antiviral activity in vitro against HSV, VZV and CMV. Although part of the latent HSV reservoir is eradicated by aciclovir in ganglionic or tissue cultures and replication is readily interrupted, reversion to latency occurs after several days of exposure.
The in vivo activity of aciclovir was demonstrated in animal models of HSV ocular, cutaneous, genital, CNS and neonatal infections. Initiation of aciclovir administration within 24 hours of viral challenge can reduce the establishment of viral latency following primary infection, but eradication of established latent virus has not been achieved. Activity as a prophylactic agent has been demonstrated in rabbits with HSV keratitis. Combination with other antiviral agents, such as vidarabine, ribavirin or ribonucleotide reductase inhibitors, has resulted in synergistic effects against HSV infections in animals.
Most aciclovir-resistant strains of HSV and VZV have mutations in the thymidine kinase gene which result in little or no production of the enzyme. Resistant HSV strains occur infrequently in immunocompetent patients, and reactivation of these strains from latency is rare. However, aciclovir-resistant HSV strains causing clinical disease are becoming increasingly common among the immunocompromised population. Reports of aciclovir-resistant strains of other herpes viruses are comparatively rare.
The pharmacokinetic disposition of intravenous aciclovir is not affected by dose, duration or frequency of administration. Steady-state plasma aciclovir concentrations in immunocompromised patients (6.7 to 20.6 mg/L after intravenous doses of 2.5 to 15.0 mg/kg every 8 hours) are similar to those obtained with equivalent single doses. Absorption of oral aciclovir is slow and variable, with a bioavailability of 15 to 30%. There is no systemic absorption of topical aciclovir from the ointment, but 30 to 50% of the drug reaches the basal epidermis in cutaneous infections treated with the cream formulation, and substantial intraocular penetration occurs with the ophthalmic ointment.
Orally or intravenously administered aciclovir is distributed to a wide range of tissues and fluids, crosses the placenta and accumulates in breast milk. Plasma protein binding is 9 to 33%, and is independent of plasma aciclovir concentrations. Drug interactions appear to be scarce. Area under the plasma concentration-time curve values and elimination half-life are increased when aciclovir and probenecid are coadministered.
The main metabolite, 9-carboxymethoxymethyl guanine, accounts for about 14% of a dose and is pharmacologically inactive. Since the main route of elimination is via renal excretion, kidney dysfunction affects plasma concentrations, extent of metabolism and rate of elimination of the drug. The elimination half-life in adults with normal renal function is 2 to 3 hours, extending to about 20 hours in patients with end-stage renal failure. The half-life in dialysis patients is 6 to 10 hours, but is prolonged to 13 to 18 hours during continuous ambulatory peritoneal dialysis. In neonates, total body clearance is reduced and elimination half-life is increased to up to 5 hours.
In Immunocompetent Patients
Double-blind placebo-controlled studies in immunocompetent patients have demonstrated the efficacy of intravenous (5 mg/kg 3 times daily), oral (200mg 5 times daily) and topical (applied 4 to 6 times daily) aciclovir initiated within 4 days of the first symptoms of HSV perigenital infection. The duration of viral shedding and time to complete healing of lesions are significantly reduced, particularly in the primary episode. Topical aciclovir is less effective in ameliorating symptoms than are the other formulations. Comparison of topical aciclovir arid intramuscular interferon-α has demonstrated no significant differences in the treatment of primary genital herpes infection, with a trend in favour of aciclovir in parameters involving time to healing, pain, and viral response. The rate of recurrence of infection is not affected by initial treatment with aciclovir.
Most well-controlled trials have shown complete suppression of genital herpes recurrence in 71 to 88% of immunocompetent patients, using prophylaxis with oral aciclovir 800 to 1000 mg/day for up to 2 years. Pretreatment recurrence rates returned on discontinuation of aciclovir. Complete suppression of recurrence for 5 years has been achieved in 20% of patients on aciclovir prophylaxis (800 to 1600 mg/day). Two well-controlled trials have demonstrated a clear advantage for oral aciclovir over oral inosine pranobex in the suppression of recurrent genital HSV infection.
Oral aciclovir therapy causes significant improvements in recurrent orofacial and cutaneous infections if begun as early as possible after reactivation. Prophylaxis with topical, and especially oral, aciclovir reduces the severity and frequency of orofacial and cutaneous HSV recurrence during treatment. Reductions in symptoms are small with topical treatment of recurrent orofacial herpes in immunocornpetent patients.
Aciclovir 3% ophthalmic ointment 5 times daily eliminates 95 to 100% of herpetic dendritic corneal ulcers in 5 to 9 days, and is at least as effective as idoxuridine 0.5 and 1.0%, trifluridine 2% and vidarabine 3% ointments. The ophthalmic ointment is also as effective as vidarabine in treating geographic corneal ulcers. Combination of aciclovir with topical interferon-α shortens the time to healing of superficial herpetic keratitis by several days compared with aciclovir alone. Oral administration of aciclovir appears to be equivalent or superior to topical administration in the treatment of herpetic disciform keratitis. Addition of topical corticosteroids to the ophthalmic ointment has proved effective in treating herpetic disciform keratitis and necrotising stromal keratitis unresponsive to single agent therapy.
Aciclovir ophthalmic ointment is as effective as vidarabine ophthalmic ointment in herpetic disciform keratitis and trifluridine ophthalmic solution in herpetic kerato-uveitis, when corticosteroids are included in the regimens. However, corticosteroids may not be necessary in patients with HSV uveitis previously untreated with corticosteroids if oral aciclovir is added to topical aciclovir therapy. Prophylaxis with oral aciclovir 800 to 1000 mg/day for 12 to 15 months completely prevented HSV keratitis recurrence in all patients undergoing penetrating keratoplasty, compared with a recurrence rate of 44% in an untreated group.
The treatment of choice for HSV encephalitis, intravenous aciclovir 10 mg/kg every 8 hours for at least 10 days, improves survival rates and reduces the incidence of serious sequelae to infection. Addition of interferon-β to the regimen provided no advantage in most patients. A placebo-controlled trial of oral aciclovir prophylaxis (800 mg/day for 26 weeks) in HSV erythema multiforme has substantiated previous reports of efficacy. Case studies have reported successful intravenous aciclovir treatment and prophylaxis in patients with HSV meningitis, and successful treatment of HSV-associated encephalitis, disseminated infection and hepatitis in pregnant women, followed by survival of mothers and infants without complications. Intravenous aciclovir and vidarabine appear equally effective in the treatment of neonatal HSV infections including mucocutaneous infection, encephalitis and disseminated disease.
There is some controversy over the role of aciclovir in treating varicella (chickenpox) in otherwise healthy individuals, since the disease is usually self-limiting. Nonetheless, oral aciclovir initiated within 24 hours of the appearance of the rash associated with varicella (chickenpox) has resulted in decreased numbers of lesions, duration of new lesion formation, severity or duration of pruritus, time to healing and duration of fever in otherwise healthy children, adolescents and adults in several well-designed studies. Clinical improvement has been noted in a few adults with varicella pneumonia receiving intravenous aciclovir, and maternal mortality rates associated with this complication have been decreased during pregnancy.
In patients with herpes zoster (shingles), intravenous (5 mg/kg every 8 hours for at least 5 days) or oral (4000 mg/day for 7 days) aciclovir treatment begun within 72 hours of exanthem onset attenuates the development of rash and pain, offers protection against ocular involvement and appears to decrease the duration of post-herpetic neuralgia. Topical idoxuridine was superior to oral aciclovir in some parameters in one double-blind study, but efficacy was similar in time to disappearance of papulopustules, appearance of first scabs, loss of all scabs, and disappearance of erythema or pain. Oral brivudine was associated with significantly greater reductions in pain and new lesion formation compared with intravenous aciclovir in elderly cancer patients with severe herpes zoster, but there were no differences in time to loss of vesicles or time to full crusting.
Although the immediate efficacy of aciclovir ophthalmic ointment in the treatment of zoster ophthalmicus is equivocal, oral aciclovir begun within 72 hours of skin eruption produces significant reductions in the longer term (up to 12 months) in frequency and severity of ocular complications such as dentriform keratopathy, stromal keratitis and anterior uveitis in these patients.
Case reports and one small placebo-controlled trial have demonstrated rapid improvement of facial function grade in patients with herpes zoster oticus treated with intravenous aciclovir, and success is also reported in isolated cases of patients with herpes zoster-associated encephalitis, myelitis, idiopathic vocal cord paralysis and Rosai Dorfman disease. Recurrence of severe almost constant aphthae has been prevented or decreased with oral aciclovir 1600 mg/day for 10 weeks.
Although trends towards faster improvement have been recorded in 2 double-blind trials of aciclovir versus placebo in patients with infectious mononucleosis, no statistically significant differences were seen. Addition of aciclovir to interferon-α therapy in patients with chronic hepatitis B appears to offer some advantages over monotherapy, but no significant differences in the rate of seroconversion were demonstrated. Aciclovir has prevented postsurgical recurrence of laryngeal papillomatosis in 3 children and improved symptoms of epilepsia partialis continua in 4 patients.
In Immunocompromised Patients
The efficacy of intravenous (250 mg/m2 every 8 hours) or oral (2000 mg/day) aciclovir is well established in the treatment of immunocompromised patients with HSV infections. Severe infections refractory to normal dosages of aciclovir (such as HSV hepatitis, or infections caused by viruses deficient in thymidine kinase activity) may respond to higher dosages, as demonstrated in case reports. Topical administration (5% in polyethylene glycol) reduced the period of viral shedding in renal transplant recipients, but the value of topical aciclovir is limited in severely immunocompromised patients.
Viral shedding and/or scabbing time, deterioration in clinical condition and progression of the disease are reduced in immunocompromised patients with VZV infections treated with intravenous aciclovir (500 mg/m2 every 8 hours for 5 to 8 days). In this setting aciclovir appears as effective as oral brivudine and at least as effective as intravenous vidarabine. Oral aciclovir is also effective in promoting healing and preventing dissemination of varicella in immunocompromised patients, and topical aciclovir reduced time to pustulation, crusting and healing in immunocompromised patients with localised herpes zoster.
Virtually complete suppression of latent HSV or VZV infections during intravenous or oral aciclovir prophylaxis has been demonstrated in most patients at increased risk of recurrence because of bone marrow transplantation, radiotherapy or cytotoxic chemotherapy, while up to 50% of infections which did recur involved asymptomatic viral shedding only. While protection was confined to the period of therapy in most patients, there is evidence that long term prophylaxis may also result in a reduction in the rate of HSV infections, compared to that seen in placebo recipients, after discontinuation of therapy. Oral aciclovir prophylaxis has provided protection against HSV and VZV infections in patients receiving renal transplants, and against HSV infections in liver and heart transplant recipients, with complete suppression of clinical symptoms during treatment in most patients. The incidence of HSV infection was also reduced in renal and heart transplant patients for up to 12 months following withdrawal of aciclovir prophylaxis.
High dose oral or continuous infusion of intravenous aciclovir have resulted in resolution of EBV infections such as oral hairy leucoplakia in immunocompromised patients, but reactivation of latent infection occurs frequently on discontinuation of the drug. Similarly, although aciclovir treatment of symptomatic CMV infection in immunocompromised patients has generally resulted in little clinical improvement, continuous infusion has resolved the infection in isolated cases.
Aciclovir prophylaxis appears to decrease CMV shedding, and reduce the incidence of clinically evident and invasive CMV disease, and possibly that of associated mortality, in immunocompromised patients with haematological disorders, despite decreased activity compared with prophylaxis against HSV and VZV. The rate of CMV infection after treatment was decreased in some patients. The incidence of CMV infection was reduced by about half (to 36%) during 1 year of observation after a 12-week course of oral aciclovir prophylaxis (800 to 3200 mg/day) in a double-blind trial in renal transplant recipients, and by half to two-thirds (to 18.3 to 30.8%) in liver transplant recipients after a 12-week course of oral aciclovir (2000 to 3200 mg/day) in several trials. Oral aciclovir plus CMV-specific immunoglobulin prophylaxis appears to offer some advantage in preventing CMV infection in patients receiving heart or lung transplants but controlled double-blind trials have not been performed in this patient population.
The effects of aciclovir alone or combined with zidovudine on laboratory measures of human immunodeficiency virus infection are equivocal, but recent double-blind studies have suggested that combined therapy may offer an advantage over zidovudine monotherapy in terms of survival and incidence of opportunistic infections in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex.
Aciclovir is well tolerated whether administered by ocular, topical, oral or intravenous routes. Adverse reactions to topical preparations have been mainly limited to mild local effects. The incidence of most adverse events, such as gastrointestinal symptoms, rash and headache, occurring during oral aciclovir therapy is similar to that seen in patients receiving placebo. There have been occasional reports of acute, usually reversible, renal failure and neurotoxicity associated with the oral formulation, but these occur more often with intravenous administration, usually in patients with high peak plasma aciclovir concentrations. Slow infusion rates, adequate hydration and lower dosages of aciclovir are recommended in patients with renal dysfunction. The effects of aciclovir on immune function have not yet been clarified. Depression of the immune response to herpesvirus antigens associated with oral and intravenous aciclovir treatment or prophylaxis in some studies is postulated to be a result of viral inhibition rather than a direct immunosuppressant effect.
Dosage and Administration
Therapy with aciclovir should be initiated as soon as possible after the onset of signs or symptoms. For dosage recommendations in specific herpesvirus infections see table XI on page 192. Dosage reductions proportional to the degree of impairment are necessary in patients with moderate to severe renal dysfunction.
KeywordsHerpes Zoster Acyclovir Varicella Zoster Virus Genital Herpes Vidarabine
Unable to display preview. Download preview PDF.
- Albeck H, Ninn-Pedersen K. Aciclovir in the treatment of facial palsy due to the zoster virus. In Danish. Ugeskrift for Laeger 151: 90–92, 1989Google Scholar
- Andreoni M, Canfarini M, Grint PCA, Martorelli M, di Luzio Paparatti U, et al. A double blind, placebo controlled trial of efficacy and safety of oral acyclovir (Zovirax®) in the treatment of chickenpox in adults. European Review for Medical and Pharmacological Sciences 14: 1–8, 1992Google Scholar
- Ashley RL, Fife K, Corey L. Specific humoral immunity in patients receiving acyclovir treatment for primary genital herpes simplex virus (HSV) infections. Abstract. Clinical Research 30: 361A, 1982Google Scholar
- Barnass S, O’Toole C, Colvin B. Cytomegalovirus infection and progression to AIDS. Lancet 2: 336, 1989Google Scholar
- Bennasr S, Brun P, Loirat C, Jacqz-Aigrain E. Aciclovir et insuffisance renale: deux cas pediatriques. Abstract no.21. Therapie 47: 223, 1992Google Scholar
- Benninger MS. Acyclovir for the treatment of idiopathic vocal fold paralysis. Ear Nose and Throat Journal 71: 207–208, 1992Google Scholar
- Berk L, Schalm SW, de Man RA, Heytink RA, Berthelot P, et al. Failure of acyclovir to enhance the antiviral effect of α lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B. A multi-centre randomized controlled trial. Journal of Hepatology 14: 305–309, 1992PubMedCrossRefGoogle Scholar
- Bowden RA, Rogers KS, Meyers JD. Oral acyclovir (ACV) for the long-term suppression of varicella zoster virus (VZV) infection after marrow transplant. Program and Abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Texas, September 17–20, 1989. Abstract no.62, p.111, 1989Google Scholar
- Brigden D, Fowle A, Rosling A. Acyclovir, a new antiherpetic drug: early experience in man with systemically administered drug. In Collier LH & Oxford J (Eds) Developments in antiviral therapy, pp. 53–62, Academic Press, London, 1980Google Scholar
- Carrier M, Pelletier GB, Cartier R, Leclerc Y, Pelletier LC. Prevention of herpes simplex virus infection by oral acyclovir after cardiac transplantation. Canadian Journal of Surgery 35: 513–516, 1992Google Scholar
- Cizman M, Mozetic M, Novakovic S, Zaletel-Kragelj L. Humoral immune response and prevention of herpes labialis after treatment of primary herpetic gingivostomatitis with acyclovir suspension. European Society for Paediatric Infectious Diseases 8th Annual Meeting, Göteborg, May 17–19, 1989. Abstract no.4. Pediatric Research 29: 116, 1991CrossRefGoogle Scholar
- Collins P, Ellis MN. Virus sensitivity following the introduction of acyclovir. Poster presented at the 18th International Congress of Chemotherapy. Stockholm, Sweden, 1993bGoogle Scholar
- Connell EV, Cerruti RL, Trowne PW. Synergistic activity of combinations of recombinant human alpha interferon and acyclovir, administered concomitantly and in sequence, against a lethal herpes simplex virus type 1 infection in mice. Antimicrobial Agents and Chemotherapy 28: 1–4, 1985PubMedCrossRefGoogle Scholar
- Crane LR, Milne DA, Sunstrum JC, Lerner AM. Comparative activities of selected combinations of vidarabine, arabinosyl hypoxanthine, interferon and polyriboinosinic acid-polyribo-cytidylic acid complex against herpes simplex virus type 2 in tissue culture and intravaginally inoculated mice. Antimicrobial Agents and Chemotherapy 26: 557–562, 1984PubMedCrossRefGoogle Scholar
- Crooks RJ, Jones DA, Fiddian AP. Zoster-associated chronic pain: an overview of clinical trials with acyclovir. Scandinavian Journal of Infection 23 (Suppl. 80): 62–68, 1991Google Scholar
- de Miranda P, Whitley RJ, Barton N, Page D, Creagh-Kirk T, et al. Systemic absorption and pharmacokinetics of acyclovir (ACV) [Zovirax] capsules in immunocompromised patients with herpesvirus infections. Abstract. 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Florida, 4–6 October, 1982bGoogle Scholar
- Douglas Jr RG, Couch RB. A prospective study of chronic herpes simplex virus infection and recurrent herpes labialis in humans. Journal of Immunology 104: 289–295, 1970Google Scholar
- Firat H, Brun P, Loirat C, Jacqz-Aigrain E. Acyclovir-induced renal failure. In French. Archives Francaises de Pediatric 49: 641–643, 1992Google Scholar
- Goldberg LH, Kaufman R, Batenhorst RL, Acyclovir Study Group. Safety and efficacy of long-term suppressive oral acyclovir (ACV) for the treatment of frequently recurring genital herpes: 4th year results. Program and Abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Texas, September 17’20, 1989. Abstract no.66, p 112, 1989Google Scholar
- Guarascio P, Farinelli G, Girardi E, Antonelli L, Tossini G, et al. Treatment of chronic hepatitis B based on interferon, acyclovir and prednisolone. Abstract. Italian Journal of Gastroenterology 22: 172, 1990Google Scholar
- Hall CB, Granoff DM, Gromisch DS, Halsey NA, Kohl S, et al. The use of oral acyclovir in otherwise healthy children with varicella. Pediatrics 91: 674–676, 1993Google Scholar
- Heidi M, Scholz H, Dörffel W, Hermann J, Wutzler P. Vergleichende Prüfung der Wirksamkeit von Bromvinyldesoxyuridin und Aciclovir bei Varicella-Zoster-Virus-Infektionen immunsupprimierter Kinder — eine prospektive randomisierte Studie. Zeitschrift fur Klinische Medizin 45: 1259–1262, 1990Google Scholar
- Hill EL, Rogers JT, Ellis MN. In vitro acyclovir susceptibility monitoring of HSV clinical isolates. Abstract no. 134. Antiviral Research 20 (suppl.1): 116, 1993Google Scholar
- Huff JC, Bean B, Balfour HH Jr, Laskin OL, Connor JD, et al. Therapy of herpes zoster with oral acyclovir. Antiviral Symposium. Amerian Journal of Medicine 85 (Suppl.2A): 84–89, 1988Google Scholar
- Johnson RE, Mullooly JP, Valanis BG, McFarland BH, Andrews EB, Tilson HH. Method of examining oral acyclovir use for adverse events. Journal of Clinical Research and Pharmacoepidemiology 5: 331–345, 1991Google Scholar
- Kingsley S. Fetal and neonatal exposure to acyclovir. Abstract. Second World Congress on Sexually Transmitted Diseases, Paris, June 1986Google Scholar
- Kowalczyk AL, Dupuis LL, Domaratzki J. Acyclovir toxicity in pediatric patients: incidence and risk factors. Abstract no. 90. Pharmacotherapy 11: 43, 1991Google Scholar
- Lassiter HA. Use of acyclovir in the treatment of chickenpox. Pediatrics 89: 1, 1992Google Scholar
- Levin MJ, Judson FN, Eron L, Bryson YJ, Corey L, et al. Comparison of intramuscular recombinant alpha interferon (rIFN-2A) with topical acyclovir for the treatment of first-episode herpes genitalis and prevention of recurrences. Antimicrobial Agents and Chemotherapy 33: 649–652, 1989PubMedCrossRefGoogle Scholar
- Littler E, Ertl P, Snowden W, Collins P. Comparative antiviral effects of acyclovir and penciclovir. Poster presented at the 18th International Congress of Chemotherapy. Stockholm, Sweden, 1993Google Scholar
- Ljungman P, Prentice HG, Powles R, Burnett A, Gluckman E, et al. Effects of high dose acyclovir on CMV infections and survival following bone marrow transplantation. Poster presented at the 4th International CMV Conference, Paris, France, 1993Google Scholar
- Meurs PF, van Bijsterveld OP. Combination therapy of recombinant human alpha 2 interferon and acyclovir in the treatment of herpes simplex keratitis. Antiviral Research (Suppl. 1): 225–228, 1985Google Scholar
- Mindel A, Weiler IVD, Faherty A, Sutherland S, Hindley D, et al. Prophylactic oral acyclovir in recurrent genital herpes. Lancet 2: 56–59, 1984Google Scholar
- Molin L, Ruhnek-Forsbeck M, Svennerholm B. One year acyclovir suppression of frequently recurring genital herpes: a study of efficacy, safety, virus sensitivity and antibody response. Scandinavian Journal of Infectious Diseases 78 (Suppl.): 33–39, 1991Google Scholar
- Mollison L, Richards M, Johnson P, Angus P, Hayes K, et al. Acyclovir reduces cytomegalovirus disease after liver transplantation. Abstract no.951. Hepatology 14: 285A, 1991Google Scholar
- Niimura M, Honda M, Nishikawa T, Kawashima M, Yasuno H, et al. The optimal concentration of aciclovir ointment for the treatment of cutaneous herpes simplex virus infections. A controlled clinical trial. Rinsho Iyaku 8: 289–297, 1992Google Scholar
- Niimura M, Yokoi K, Aoki I, Yamaguchi M. Single dose study and multiple dose study to evaluate safety and pharmacokinetics of aciclovir ointment in healthy volunteers. Rinsho Iyaku 6: 15–22, 1990aGoogle Scholar
- Niimura M, Yokoi K, Yamaguchi M, Yasuda K, Onishi A. Patch test of aciclovir ointment in healthy volunteers. Rinsho Iyaku 6: 9–14, 1990bGoogle Scholar
- Palmieri G, Bucci L, Contos S, Ferrante P. Comparison of two acyclovir tablet formulations for acute herpes zoster treatment. Abstract no.177. Antiviral Research 20 (Suppl. 1): 138, 1993Google Scholar
- Peitier MKH, Weisdorf D. Efficacy of low-dose acyclovir for herpes simplex virus (HSV) prophylaxis in bone marrow transplant (BMT) patients. Abstract no.93. Pharmacotherapy 11: 278, 1991Google Scholar
- Ragazzo PC, Zanini LA, Cendes F, deAzevedo L. Control of continuous partial motor seizures in Rasmussen encephalitis during therapy with acyclovir. Epilepsia 32: 91, 1991Google Scholar
- Safrin S, Schacker T, Delehanty J, Hill E, Corey L. Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir. Antimicrobial Agents and Chemotherapy 37: 975–979, 1993PubMedCrossRefGoogle Scholar
- Shishkov S, Pancheva S. Synergistic antiviral effect of acyclovir and ribavirin towards herpes simplex virus type 1 and the virus of pseudorabias in vitro. In Russian. Acta Microbiologica Bulgarica 25: 69–75, 1990Google Scholar
- Spector T. 348U87: an inactivator of herpes virus ribonucleotide reductase that potentiates the antiviral activity of acyclovir. Drugs of the Future 18: 25–28, 1993Google Scholar
- Spruance SL, Freeman DJ, Stewart JCB, McKeough MB, Wenerstrom LG, et al. The natural history of ultraviolet radiationinduced herpes simplex labialis and response to therapy with peroral and topical formulations of acyclovir. Journal of Infectious Diseases 163: 728–734, 1991PubMedCrossRefGoogle Scholar
- Sutton D, Taylor J, Bacon TH, Boyd MR. Activity of penciclovir in combination with azidothymidine, ganciclovir, acyclovir, foscarnet and human interferons against herpes simplex virus replication in cell culture. Antiviral Chemistry and Chemotherapy 3: 85–94, 1992Google Scholar
- Swan SK, Bennett WM. Oral acyclovir and neurotoxicity. Annals of Internal Medicine 3: 188, 1989Google Scholar
- Tanna S, Wood C, Lawrence MJ. Competition studies to elucidate the mechanisms of acyclovir uptake in the small intestine. Journal of Pharmacy and Pharmacology 44 (Suppl.): 1047, 1992Google Scholar
- Tartaglione TA, Collier AC, Opheim K, Gianola FG, Benedetti J, et al. Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy 35: 2225–2231, 1991PubMedCrossRefGoogle Scholar
- Tatnall FM, Schofield J, Proby C, Leigh IM. A double blind placebo controlled trial of continuous acyclovir in recurrent erythema multiforme. Abstract. British Journal of Dermatology 125 (Suppl. 38): 29, 1991Google Scholar
- Uri N, Greenberg E, Meyer W, Kitzes-Cohen R. Herpes zoster oticus: treatment with acyclovir. Annals of Otology, Rhinology and Laryngology 101: 161–162, 1992Google Scholar
- Vajpayee RB, Gupta SK, Beraja U, Mohan M. Evaluation of acyclovir in the management of various types of herpetic corneal lesions: a prospective controlled clinical trial in 34 patients. Medical Science Research 17: 93–94, 1989Google Scholar
- Van Dyke R, Straube R, Large K, Hintz M, Spector S, et al. Pharmacokinetics of increased dose oral acyclovir. Abstract. 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Florida, 4–6 October 1982Google Scholar
- Velasco M, Saavedra T, Sepulveda C, Suarez M. Prolonged treatment of recurrent genital herpes with oral acyclovir. In Spanish. Revista Medica de Chile 119: 876–880, 1991Google Scholar
- Vere Hodge RA. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antiviral Chemistry and Chemotherapy 4: 67–84, 1993Google Scholar
- Wirth S, Ehninger G, Baumann W Zur Behandlung konnataler Varizelien mit Acyclovir. Monatsschrift fur Kinderheilkunde 135: 696–698, 1987Google Scholar
- Wutke K, Wutzler P, Alken RG, Kowal K. BVDU (bromovinyl-desoxyuridine) versus aciclovir: therapy of severe herpes zoster in cancer patients. Results of a double-blind trial. Abstract no. 58. Onkologie 14 (Suppl.3): 21, 1991Google Scholar
- Youle MS, Gazzard BG, Johnson MA, Cooper DA, Hoy JF, et al. Effects of high dose oral acyclovir on cytomegalovirus (CMV) disease and survival in patients with advanced HIV disease. Poster presented at the 4th International CMV Conference, Paris, France, 1993Google Scholar
- Zandotti C, de Lamballerie X, Viard L, Noirclerc M, de Micco P. Acyclovir and immune globulin prevention and ganciclovir treatment of cytomegalovirus infections in children after lung transplantation: analysis of 12 patients. Médecine et Maladies Infectieuses 22 (Suppl.): 606–609, 1992CrossRefGoogle Scholar